Dana-Farber/Boston Children's is an international leader in improving treatment and quality of life for children affected by sickle cell disease. We treat sickle cell anemia (HbSS), sickle cell with hemoglobin C disease (HbSC), hemoglobin S-beta-thalassemia (HbS?0 and Hb?+ thalassemia), and less common compound forms, including HbSD, HbSO and HbSE. Through our Sickle Cell Disease Program, children have access to world-renown pediatric hematologists, top-rated nursing care, and the latest treatment options including hydroxyurea and stem cell transplantation. We are also one of the few centers in the nation using a new type of technology, called PreciseType, to precisely match blood donors to sickle cell patients who need blood transfusion.
Partial Data by Infogroup (c) 2024. All rights reserved.